

1

2 **Supplementary Information for**
3 **Decreasing measles burden by optimizing campaign timing**
4 **Niket Thakkar, Syed Saqlain Ahmad Gilani, Quamrul Hasan and Kevin McCarthy**
5 **Correspondence should be addressed to nthakkar@idmod.org**

6 **This PDF file includes:**

- 7 Supplementary text
- 8 Figs. S1 to S12
- 9 Tables S1 to S3
- 10 References for SI reference citations

Supporting Information Text

1. Data sources and processing

Data used throughout the paper comes from three major sources: WorldPop population and birth rasters (1–3), Pakistan’s most recent Demographic and Health Survey (4), and lab reports from Pakistan’s measles surveillance system. In this section, we provide some details on where this data can be obtained and how it was processed.

Lab confirmed and rejected cases. Lab reports come from Pakistan’s WHO affiliated lab in compliance with WHO surveillance standards (5). Briefly, all individuals presenting with fever, rash, and one of the 3 C’s (cough, coryza, or conjunctivitis) are suspected of having measles and should in principle have blood drawn for lab confirmation. In practice however, not all suspected measles cases are lab confirmed, and we model selection as a random process. Blood samples are then sent to a national lab where IgM assays are used to confirm or reject measles infection. The lab reports used in this study record lab activity over time with entries for each serum sample giving a location, birth-date, caregiver-reported dose history, and classification (measles positive or negative).

Population. Populations rasters for Pakistan in 2010 and 2015 were obtained from the WorldPop website (worldpop.org.uk) (1–3), and pixel level population estimates were aggregated by district to produce the map in Fig. S1. Data was aggregated further to province or national level by summing the population by district.

Population estimates were linearly interpolated in time. This is shown for Sindh in Fig. S2. Linear interpolation between WorldPop estimates creates a ramp from 2010 to 2015. The time series is then extrapolated by assuming a constant population on either end.

Birth rate. Province-level birth rate estimates were also obtained from WorldPop by processing 2010, 2012, 2015, and 2020 live-birth rasters in the same method as above. These rasters covered all the provinces modeled except for Gilgit Baltistan.

To obtain an estimate for Gilgit Baltistan, we used the 2012-13 DHS. The method we used varies from DHS specifications (6) by not using age-based fertility as an intermediate step and by using a fixed three-year window to count births. All estimates were computed in consideration of the complex survey design and corresponding sample weights using the `survey` package in R (7, 8), and we verified that the birthrates based on WorldPop estimates (where available) and these province-level DHS estimates are comparable. Birth rates are summarized in Table S1.

Vaccination coverage. Estimates of measles containing vaccine (MCV) coverage were obtained directly from the 2012-2013 DHS (4) and assumed constant throughout the modeled time period. These estimates, plotted in Fig. S3, were taken as estimates of single-dose routine immunization coverage since the survey asks this question of 12-23 month olds.

The WHO also recommends a second MCV dose (MCV2) at 15 months of age. Coverage for MCV2 was estimated by analyzing the percentage of rejected measles cases with 2 vaccines self reported in their dose histories. This method is very coarse, and estimating uncertainty is difficult. For our modeling purposes, we assume coverage uncertainty is small compared to transmission and reporting uncertainty, and it’s therefore neglected. Still, more accurate estimation of MCV2 coverage is a topic of current research. Here, MCV2 rates were also assumed constant in the model time period. Coverage values are summarized in Table S2.

In the model, coverage numbers are used to calculate the number of births missed by RI. This calculation requires an assumption about MCV take (the probability that vaccination results in immunity), which is known to vary with age and depend on environmental factors like MCV cold-chain. This is a complicated issue, and in line with others (9), we greatly simplify the calculation by assuming MCV1 take is 90% and MCV2 take is 99% throughout the entire country during the entire model period. In that case, adjusted births, B_t , can be calculated from total births \tilde{B}_t , via

$$B_t = \tilde{B}_t [1 - 0.9V_{1,t}(1 - V_{2,t}) - 0.99V_{1,t}V_{2,t}], \quad [1]$$

where $V_{1,t}$ and $V_{2,t}$ are MCV1 and MCV2 coverages respectively. This calculation incorporates all coverage information into the model, and we have found further that model projections are robust to reasonable changes in MCV take (from 80% to 95%). It is worth noting however, that considerable uncertainty is being ignored when we approximate the semi-monthly number of children added to the susceptible pool by this deterministic time series. In principle, heterogeneity in the waning of maternal antibodies (10), the timing if MCV doses, and the birth-rate from semi-month to semi-month all contribute to uncertainty in the number of births over time. However, for our purposes of projecting total infections from 2018-2021, we anticipate that transmission stochasticity is a larger driver of overall uncertainty, and noise in the number of children missed by RI can be ignored.

2. A TSIR model with vaccination campaigns

Our model of measles is an extension of the time series susceptible-infected-recovered (TSIR) model of Finkenstädt and Grenfell(11), incorporating the effects of vaccination campaigns into calibration. Inspired by the traditional SIR model (12), we assume the interacting susceptible population, S_t , and infectious population, I_t , obey discrete time, stochastic dynamical




Fig. S1. The population estimates used in this study were generated by aggregating WorldPop rasters to district level, shown here in 2015.




Fig. S2. Both population and birth-rate are linearly interpolated in time with constant extrapolation. This produces a ramp between rasters with plateaus on either end.

Province	Birth rate (WorldPop)	Birth rate (2012 DHS)
Balochistan	1.004	1.193
Gilgit Baltistan	Not available	1.0373
Islamabad	1.038	0.832
Khyber Pakhtoon	1.103	1.122
Punjab	1.059	1.142
Sindh	1.0823	1.091

Table S1. Time averaged birthrates (per 100k, per semi-month) computed via WorldPop rasters and the DHS. Since the WorldPop rasters have better time resolution, we default to WorldPop estimates where they're available, using the DHS only in Gilgit Baltistan.




Fig. S3. Coverage of the first dose of routine vaccination was taken from the 2012-13 DHS measles vaccination coverage in 12-23 month olds by province and assumed constant throughout the modeled time period.

Province	MCV1 coverage (DHS)	MCV2 coverage (rejected cases)
Balochistan	0.381	0.079
Gilgit Baltistan	0.510	0.314
Islamabad	0.852	0.214
Khyber Pakhtoon	0.577	0.222
Punjab	0.696	0.563
Sindh	0.451	0.273

Table S2. MCV1 and MCV2 coverage estimates via the DHS and rejected measles cases. For MCV2 coverage estimates, rejected measles cases are assumed to be a sample of children from a given region. MCV2 coverage is estimated by computing the fraction of samples with 2 or more self-reported MCV doses.

equations,

$$S_t = (1 - \mu_{t-1})(B_t + S_{t-1} - I_t) \quad [2]$$

$$I_t = \beta_t I_{t-1}^\alpha S_{t-1} \varepsilon_t, \quad [3]$$

where time is taken in semi-monthly increments corresponding to the average duration of a measles infection (10). This choice allows us to compare I_t , the prevalence at time t , with observed cases, C_t , a measure of incidence. In the above equations, B_t is the estimate of the number of births missed by RI per semi-month described previously, μ_t is the efficacy of any SIA at time t , β_t is the time-dependent transmission rate which we assume has annual periodicity, and α accounts for inhomogeneous mixing (11). Transmission uncertainty is modeled by ε_t , a log-normally distributed random variable with zero mean and constant variance, and reporting uncertainty is modeled by assuming

$$C_t \sim \text{Binom} \left\{ I_t, p = \frac{1}{\rho} \right\}, \quad [4]$$

where p is the lab-reporting-rate, the probability of a measles infection to be selected for lab-confirmation. All other sources of uncertainty, in population estimates for example, are assumed to be negligibly small.

In this section, we describe the method used to fit this model to lab-confirmed measles cases from Pakistan. Given SIA coverages μ_t , this requires two regressions, one to reconstruct the underlying susceptible population and another to determine the transmission seasonality.

Reconstructing S_t . Susceptible reconstruction requires us to account for uncertainty due to under-reporting and to relate observed cases to underlying prevalence. Under the binomial reporting model, we have

$$[C_t | I_t, p] = \binom{I_t}{C_t} p^{C_t} (1-p)^{I_t-C_t}, \quad [5]$$

where $[\cdot]$ denotes a probability distribution or density. Via Bayes' theorem with a uniform prior enforcing $I_t \geq C_t$, this implies

$$[I_t | C_t, p] = \binom{I_t}{C_t} p^{C_t+1} (1-p)^{I_t-C_t}, \quad [6]$$

where we continue to assume p is known. Using a moment generating function approach, this yields

$$\mathbb{E}[I_t | C_t, p] = \frac{1}{p}(C_t + 1) - 1, \quad [7]$$

$$\text{Var}[I_t | C_t, p] = \frac{1-p}{p^2}(C_t + 1). \quad [8]$$

Setting these results aside for a moment, we return to Eq. 2. Following Finkenstädt and Grenfell (11), we assume $S_t = \bar{S} + Z_t$, where \bar{S} is an average susceptible population and Z_t are time-dependent fluctuations around this average. Inserting this decomposition into Eq. 2,

$$\begin{aligned} \bar{S} + Z_t &= (1 - \mu_{t-1})(\bar{S} + Z_{t-1} + B_t - I_t) \\ \Rightarrow Z_t &= -\mu_{t-1}\bar{S} + (1 - \mu_{t-1})(Z_{t-1} + B_t - I_t). \end{aligned} \quad [9]$$

This relation can be usefully rewritten in linear-algebra notation. Treating time dependent quantities as column vectors with ordered entries for each semi-month in the modeling period,

$$\mathbf{Z}_t = \mathbf{A}\mathbf{B}_t - \mathbf{A}\mathbf{I}_t - \bar{S}\mathbf{D}\mathbf{m}_t, \quad [10]$$

where

$$\mathbf{A} = \begin{bmatrix} 1 & 0 & 0 & 0 & 0 & \dots \\ (1-\mu_0) & (1-\mu_0) & 0 & 0 & 0 & \dots \\ (1-\mu_0)(1-\mu_1) & (1-\mu_0)(1-\mu_1) & (1-\mu_1) & 0 & 0 & \dots \\ \vdots & \vdots & (1-\mu_1)(1-\mu_2) & (1-\mu_2) & 0 & \dots \\ \vdots & \vdots & \vdots & (1-\mu_2)(1-\mu_3) & \dots & \dots \\ \vdots & \vdots & \vdots & \vdots & \dots & \dots \end{bmatrix} \quad [11]$$

and

$$\mathbf{D} = \begin{bmatrix} 0 & 0 & 0 & 0 & 0 & \dots \\ 0 & (1-\mu_0) & 0 & 0 & 0 & \dots \\ 0 & (1-\mu_0)(1-\mu_1) & (1-\mu_1) & 0 & 0 & \dots \\ \vdots & \vdots & (1-\mu_1)(1-\mu_2) & (1-\mu_2) & 0 & \dots \\ \vdots & \vdots & \vdots & (1-\mu_2)(1-\mu_3) & \dots & \dots \\ \vdots & \vdots & \vdots & \vdots & \dots & \dots \end{bmatrix} \quad [12]$$

88 In other words, \mathbf{A} and \mathbf{D} are linear transformations (both dimension $(t+1) \times (t+1)$) based on the cumulative product of the
 89 μ_t time series. Finally,

$$\mathbf{m}_t = \begin{bmatrix} 0 \\ \frac{\mu_0}{1-\mu_0} \\ \frac{\mu_1}{1-\mu_1} \\ \frac{\mu_2}{1-\mu_2} \\ \vdots \\ \frac{\mu_{t-2}}{1-\mu_{t-2}} \\ \frac{\mu_{t-1}}{1-\mu_{t-1}} \end{bmatrix}, \quad [13]$$

a time-series based on past SIA efficacy. Under the assumption that \mathbf{B}_t and \mathbf{m}_t are known with negligible uncertainty, Eqs. 7 and 8 imply

$$\mathbb{E}[\mathbf{Z}_t | \mathbf{C}_t, p] = \mathbf{A}(\mathbf{B}_t + 1) - \frac{1}{p} \mathbf{A}(\mathbf{C}_t + 1) - \bar{S} \mathbf{D} \mathbf{m}_t, \quad [14]$$

$$\text{Var}[\mathbf{Z}_t | \mathbf{C}_t, p] = \mathbf{A} \left(\frac{1-p}{p^2} (\mathbf{C}_t + 1) \right) \mathbf{A}^T \propto \mathbf{C}_t + 1 \quad [15]$$

91 where scalar addition to column vectors is applied element-by-element. Under the assumption that fluctuations in S_t will be
 92 small, Eq. 14 motivates a weighted least-squares regression of $\mathbf{A}(\mathbf{B}_t + 1)$ against $\mathbf{A}(\mathbf{C}_t + 1)$ and $\mathbf{D} \mathbf{m}_t$ to approximate $1/p$.
 93 Weights are assumed equal to $1/\sqrt{\mathbf{C}_t + 1}$ and regression residuals then approximate $\mathbb{E}[\mathbf{Z}_t]$. Thus, this procedure gives an
 94 estimate of p and the fluctuations in underlying susceptible population, \mathbf{Z}_t .

95 As a brief aside, we note that the reporting rates, p , are an interesting model output on their own, and we are continuing to
 96 study the spatial heterogeneity in p throughout Pakistan. One interesting comparison is plotted in Fig. S4. Here, the rate per
 97 100k per year of rejected (i.e. non-measles) lab reports is averaged for each province from 2012-2017, offering an independent
 98 metric for the activity of the surveillance system in each province. We find that our inferred reporting rates, which are based
 99 on confirmed cases, are highly correlated, lending confidence to our modeling procedure.

100 **Estimating β_t .** Analysis of Eq. 3 offers a route to estimate the remaining parameters. Taking the log, we have

$$\log I_t = \log \beta_t + \alpha \log I_{t-1} + \log S_{t-1} + \log \varepsilon_t, \quad [16]$$

102 where $\mathbb{E}[\log \varepsilon_t] = 0$ and $\text{Var}[\log \varepsilon_t] = \sigma$. Here we follow Finkenstädt and Grenfell (11) exactly, and we assume

$$\log S_t = \log (\bar{S} + Z_t) \approx \log \bar{S} + \frac{Z_t}{\bar{S}}, \quad [17]$$

104 where we have used the first order Taylor expansion for the log under the assumption that Z_t is small. Inserting this result into
 105 Eq. 16, we find

$$\log I_t = \log (\bar{S} \beta_t) + \alpha \log I_{t-1} + \frac{Z_{t-1}}{\bar{S}} + \log \varepsilon_t. \quad [18]$$

107 This motivates the second regression. The first term is treated as an intercept for each semi-month of a given year and α and
 108 $1/\bar{S}$ are slopes. Z_t is replaced with $\mathbb{E}[Z_t]$ from the previous regression, and I_t is taken to be $[(C_t + 1)/p] - 1$ with p also from
 109 the previous regression. Finally, σ , the variance associated with transmission uncertainty, is estimated using the regression's
 110 residual variance.

111 **Estimating μ_t .** The method outlined in the previous subsections can be used to estimate all model unknowns except SIA
 112 efficacies. As described in the main text, approximating μ_t can be reduced to estimating a single parameter since Pakistan has
 113 had a relatively small number of measles SIAs.

114 We assume that $\mu_t = \mu P_t$, where μ is an SIA efficacy parameter common to all campaigns from 2012-2017 and P_t is an
 115 estimate of the fraction of the population targeted in a given campaign. P_t is approximated using population estimates at
 116 district level in combination with WHO descriptions of regions targeted by each SIA (13). Age ranges of the campaigns are
 117 also incorporated by comparing the target populations among campaigns with different age ranges in the same regions. SIA
 118 dates are rounded to the nearest semi-month. For example, in 2017, two districts in Sindh were targeted, representing $\sim 15\%$
 119 of Sindh's total population. For reference, P_t is tabulated in Table S3.

120 Specifying μ_t thus requires us to estimate a single parameter. We do this by iterating the regression procedure above
 121 for a set of possible μ and comparing goodness-of-fit. More specifically, given a hypothetical μ , we estimate the remaining
 122 free parameters, compute the average long-term extrapolation (Fig. 2 in the main text), and calculate R^2 for the 2015-17
 123 time-period. Restriction to the later years is made to emphasize fit quality closer to when competing SIA policies are to be
 124 tested. This method is closely related to the profile likelihood optimization procedures employed by others (14, 15).

125 The results of this approach applied to the Pakistan data are plotted in Fig. S5. R^2 values (grey, dashed) are smoothed
 126 with a 30 point, centered rolling average (black) and the highest R^2 value is selected (red circle). This yields $\mu \approx 0.40$ with an
 127 $R^2 \approx 0.6$ for the 2015-2017 model period.




Fig. S4. Rejected cases, so-called non-measles febrile rash reports, per 100k per year averaged from 2012-2017 is a potential indicator of the activity of a province-wide surveillance system. We find that our inferred reporting rates (red dots) and computed rejected case rates are highly correlated (grey line is a least squares fit).

Province	Date	Target population fraction (P_t)
AJK	2011-11-30	1.00
	2014-12-15	1.00
Balochistan	2010-09-30	0.10
	2011-01-15	0.11
	2012-12-31	0.81
	2015-04-30	1.00
	2015-08-31	1.00
FATA	2015-08-31	1.00
Gilgit Baltistan	2011-07-15	1.00
	2015-05-31	1.00
Islamabad	2015-02-28	1.00
Khyber Pakhtoon	2010-09-30	0.60
	2011-01-31	0.25
	2014-05-31	1.00
	2010-09-30	0.18
Punjab	2011-01-31	0.36
	2013-05-15	0.66
	2015-02-15	1.00
	2010-10-31	0.39
	2011-01-15	0.18
Sindh	2011-02-28	0.42
	2013-05-15	0.66
	2014-05-31	1.00
	2017-08-15	0.15

Table S3. Tabulated target population fractions from the WHO SIA calendar and SIA reports (13). For all dates not included, $P_t = 0$. Note that, while we have this information for AJK and FATA, lack of other data (RI coverage for example) prevents modeling, and we ignore those campaigns in the analysis.




Fig. S5. Optimization for μ is carried out by repeated fitting and model testing. Comparing goodness-of-fit (measured via R^2 in the 2015-2017 model period) yields $\mu \approx 0.4$.

3. Comparing future timing-efficacy combinations

To evaluate the impact of future SIAs, we sample the calibrated model and sum the infections calculated with an extrapolation starting at end of the lab reports in 2017. In the main text, for simplicity, we restrict this comparison to a future efficacy of 0.4, equal to the historically precedented value according to our inference procedure above. In principle however, the efficacy in the future could change, and here we discuss results as a function of both efficacy and timing.

Fig. S6 summarizes the expected infections as a function of SIA policy. Each dot is the average of 5000 samples of infections from 2018-2021 with SIAs at a particular time (x-axis) and efficacy (colorbar, which indicates the absolute value and the value relative to the historical average). Timing behaves just as discussed in the main text, with a precipitous decrease in cases over the course of the 2018 low transmission season leading to an optimum for a given efficacy at October-November.

Contours at future SIA efficacy equal to 0.3, (red), 0.4 (orange), and 0.5 (green) show that increasing SIA efficacy universally decreases total infections, just as we would expect. This type of analysis is useful when trying to understand the trade-off between delaying (potentially increasing burden) and increasing time to plan (potentially increasing efficacy).

4. Testing province-level models

The model can be generalized to province level by assuming transmission related parameters (i.e. those in Eq. 3) remain qualitatively the same and refitting the remaining parameters using data relevant to the province in question. More specifically, we assume β_t from the national level can be scaled by the fraction of the total population in the province of interest to model contact rate's dependence on total population. Then, S_t is reconstructed using the method above with birth, coverage, and case data specific to the province being modeled.

Sparsity of data at the province level necessitates these fairly severe modeling assumptions even though there is no general reason to believe transmission seasonality is qualitatively similar across provinces. On top of this, we ignore transmission and importation between provinces, an effect which has likely occurred in past outbreaks (16). Incorporation of inter-province correlation is a topic of current research.

Even under these assumptions, we can verify that our province level models forecast effectively, indicating that we have captured dominant effects at this spatial scale. In Figs S7-S12, calibration tests like those of Fig. 2 in the main text are shown for each province. We see universally that long-term extrapolation is possible and accurately predicts future outbreaks, even in provinces with relatively small population. This gives us confidence in the models' 2018-2021 projections, which are shown in these figures in the absence of a 2018 SIA.

References

1. Tatem AJ (2017) Worldpop, open data for spatial demography. *Scientific data* 4:170004–170004.
2. Tatem AJ, et al. (2014) Mapping for maternal and newborn health: the distributions of women of childbearing age, pregnancies and births. *International journal of health geographics* 13(1):2.
3. Gaughan AE, Stevens FR, Linard C, Jia P, Tatem AJ (2013) High resolution population distribution maps for Southeast Asia in 2010 and 2015. *PloS one* 8(2):e55882.
4. (2013). National Institute of Population Studies - NIPS/Pakistan and ICF International, “Pakistan Demographic and Health Survey 2012-13”.
5. (2003). World Health Organization, “WHO-recommended standards for surveillance of selected vaccine preventable diseases”.
6. Rutstein SO (2006) Guide to DHS statistics.
7. Lumley T (2004) Analysis of complex survey samples. *Journal of Statistical Software* 9(1):1–19. R package version 2.2.
8. Lumley T (2016) survey: analysis of complex survey samples. R package version 3.32.
9. Simons E, et al. (2012) Assessment of the 2010 global measles mortality reduction goal: results from a model of surveillance data. *The Lancet* 379(9832):2173–2178.
10. Plotkin S, Orenstein W, Offit P, Edwards KM (2017) *Plotkin's Vaccines*. (Elsevier), 7 edition.
11. Finkenstädt BF, Grenfell BT (2000) Time series modelling of childhood diseases: a dynamical systems approach. *Journal of the Royal Statistical Society: Series C (Applied Statistics)* 49(2):187–205.
12. Keeling MJ, Rohani P (2011) *Modeling infectious diseases in humans and animals*. (Princeton University Press).
13. (2017). World Health Organization. “Summary of measles-rubella supplementary immunization activities”, (http://www.who.int/immunization/monitoring_surveillance/data/en/).
14. Ionides EL, Bretó C, King AA (2006) Inference for nonlinear dynamical systems. *Proceedings of the National Academy of Sciences* 103(49):18438–18443.
15. Ionides EL, Nguyen D, Atchadé Y, Stoev S, King AA (2015) Inference for dynamic and latent variable models via iterated, perturbed Bayes maps. *Proceedings of the National Academy of Sciences* 112(3):719–724.
16. Khan T, Qazi J (2014) Measles outbreaks in pakistan: causes of the tragedy and future implications. *Epidemiology Reports* 2(1):1.




Fig. S6. Once calibrated, the model can be used to test future SIAs with varying efficacy and timing. Dots represent expected infections from 2018-21 as a function of timing with SIA efficacy proportional to color (colorbar, with value relative to inferred μ indicated). Efficacy contours at 0.3 (red), 0.4 (orange), and 0.5 (green) qualitatively demonstrate that infections fall regardless of timing as efficacy increases.




Fig. S7. Model testing and performance for Sindh.




Fig. S8. Model testing and performance for Punjab.




Fig. S9. Model testing and performance for Balochistan.




Fig. S10. Model testing and performance for Gilgit Baltistan.




Fig. S11. Model testing and performance for Islamabad.




Fig. S12. Model testing and performance for Khyber Pakhtoon.